This study identified six lncRNAs (SLC12A5-AS1, MAP3K2-DT, LINC02544, MIR181A2HG, LINC01914, and LNCOG) whose expression is significantly upregulated in gastric cancer. High expression of these lncRNAs is associated with unfavourable overall survival, particularly for LNCOG, LINC02544, and SLC12A5-AS1 after adjustment. Co-expression network analyses highlighted the involvement of these lncRNAs in cancer-associated pathways, notably epithelial-mesenchymal transition. These lncRNAs may hold diagnostic and prognostic value, although independent validations are required.
This retrospective study investigated Claudin 18.2 (CLDN18.2) expression via immunohistochemistry in 64 patients with advanced gastrointestinal peritoneal disease. The aim was to assess CLDN18.2's potential as a therapeutic target beyond upper gastrointestinal cancers. Results revealed significant CLDN18.2 expression in a subset of appendiceal peritoneal metastases, particularly in high-grade appendiceal mucinous carcinomas (22% strong positivity). In contrast, expression was low in colorectal adenocarcinomas. These findings suggest CLDN18.2 could be a promising therapeutic target for patients with appendiceal mucinous carcinomas, potentially offering new options where curative treatments are limited.
This study employed a deep learning-based graph neural network model to identify genes and pathogenic genetic variations driving gastric cancer pathogenesis. Researchers focused on tumor suppressor proteins exhibiting both dysregulated expression and high mutation propensity. The model identified 1,886 relevant genes, with TP53, ERBB2, CDH1, and APC emerging as prominent hub genes. Missense and nonsense variants in TP53, CDH1, and APC were validated, affecting post-translational modification sites and correlating with altered patient survival. The study also highlighted EZH2 and miR-129-5p as key regulators and the dysregulation of oncogenes like CCNE1/2 and FGFR2.
This study investigated the expression of SWI/SNF chromatin remodeling complex genes and its subtypes (cBAF, PBAF, GBAF) across 33 tumor types, utilizing DNA and mRNA data from The Cancer Genome Atlas (approximately 11,000 samples). Researchers found that the expression of certain genes like ACTL6B, DPF1, DPF3, and SMARCD3 varied most among tumor types, with 10 out of 33 tumor types exhibiting distinct expression signatures. While SWI/SNF gene mutations resulted in only minor changes in their own expression, they were linked to downstream regulation of transcriptional programs associated with epigenetic regulation, particularly in colon adenocarcinoma, kidney renal clear cell carcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. These findings could contribute to the development of biomarkers and targeted therapies.
This multicenter study developed a multimodal model (MuMo) to assess the prognosis of patients with locally advanced gastric cancer following neoadjuvant therapy. The model integrates radiomic features from preoperative CT images, post-neoadjuvant therapy transcriptomic sequencing data, and clinicopathological information. Machine learning algorithms identified independent radiomic and molecular risk factors. MuMo demonstrated superior performance compared to single-modality models and ypTNM staging in predicting overall and disease-free survival, suggesting the involvement of immune-inflammatory pathways in therapy efficacy.
This study developed and evaluated an optimized intramuscular patient-derived xenograft (PDX) platform for gastric cancer. The model achieved a high engraftment rate of 71.7%, significantly exceeding conventional methods. Researchers utilized whole exome sequencing to identify divergent driver mutations between fast- and slow-growing tumors. The findings suggest that PDX-guided chemotherapy selection is associated with improved progression-free survival, and that driver mutation profiles can serve as prognostic biomarkers.
This phase 2 study investigated the addition of tislelizumab to perioperative chemotherapy for patients with locally advanced gastric or gastroesophageal junction cancer. Patients were stratified by tumor-specific MHC class II (tsMHC-II) expression. The findings revealed that the combination immunotherapy significantly increased the major pathological response (mPR) rate in tsMHC-II-positive patients (61.8% vs. 26.5% with chemotherapy alone). No benefit was observed in the tsMHC-II-negative subgroup, indicating tsMHC-II as a promising predictive biomarker.
This real-world study analyzed the genomic landscape of GNAQ and GNA11 mutations in 5,416 patients with metastatic solid tumors. It revealed that these mutations, while known in uveal melanoma, are also present in other cancers such as colorectal, melanoma, and gastric cancer. An immunogenic subgroup, characterized by non-hotspot mutations and high TMB or MSI, was identified and associated with potential benefit from immune checkpoint inhibitors. Canonical hotspot mutations, conversely, were predominant in TMB-low/MSS tumors. These findings highlight the importance of differentiating driver mutations from bystander mutations to guide therapeutic strategies.
This study investigated additional genetic alterations in MET-amplified gastric cancers (GCs), which are associated with poor prognosis and limited response to targeted therapies. Researchers found that MET amplification is frequently accompanied by co-amplifications of other oncogenes located on chromosome 7, such as BRAF, CDK6, and EGFR, in 54% of cases. These co-amplifications exhibit significant intra- and intertumoral heterogeneity. This complex heterogeneity may explain the diagnostic and therapeutic challenges, subclonal evolution, and the failure of targeted therapies in MET-amplified GCs.
This study investigated the role of the LMBR1L protein in gastric cancer, revealing its significant overexpression in tumor tissues. Patients with high LMBR1L levels exhibited reduced postoperative overall and disease-free survival rates. Multivariate analyses confirmed LMBR1L expression as an independent risk factor for gastric cancer patient prognosis. Furthermore, a nomogram model incorporating LMBR1L demonstrated good predictive value for postoperative survival. In vivo experiments also indicated that LMBR1L knockdown significantly inhibits tumor growth.